



ASX Release

Quarterly Cash Flow Report

Quarter ended 31 December 2015

Melbourne, Australia; 29 January 2016: Jayex Healthcare Limited (ASX:JHL) (**Jayex** or **Company**), a leading e-health provider of integrated healthcare services delivery platforms, today released its Appendix 4C – Quarterly cash flow report for the quarter ended 31 December 2015 (the **Quarter**), its first since its ASX listing in December 2015.

Highlights for the Quarter

- Fully funded operations with successful \$8m Initial Public offering (**IPO**) and ASX listing
- Completed consolidation of Jayex group with the acquisition of Jayex UK
- Strong growth in *Enlighten* business with 46 kiosks sold during the quarter and Expressions of Interest growing to 534 additional medical centres
- Trials of *Enlighten* underway for three major medical centre operators with 100 centres
- Commenced expansion of *Enlighten* into the Australian Allied Healthcare Practice market, which is significantly larger than the size of the GP clinic market

Key Points – Operational

The Company has continued to make very good progress on the commercialisation of the *Enlighten* patient workflow platform, and the development and commercialisation of the *Appointuit* patient engagement solution in the Australian market.

During the Quarter, the Company sold 46 *Enlighten* kiosks in Australia, bringing the total for 2015 to 118 *Enlighten* devices to customers in Australia, including 13 to hospitals and 105 to GP clinics. At the end for the Quarter, the Company also had 2,291 *Appointuit* health care practitioners.

Looking forward there is strong and growing interest from Australian medical centre operators for the *Enlighten* offering. At the end of the Quarter, the Company had received expressions of interest covering 534 sites, which we believe is result of having completed secure technical integrations of *Enlighten* with Australia's four most popular GP Practice Management Software systems - Best Practice, Medical Director, Zedmed and Genie. Another future growth opportunity is the Australian Allied Healthcare Practice (AHP) market which is significantly larger than the size of the Australian GP clinic market. Entry into the AHP market is well advanced and during the Quarter, the Company completed the technical integration of its *Enlighten* technology with PPMP, an Australian provider of Patient Management Software (PMS) to over 1,300 AHPs, predominately physiotherapists.

In the Quarter, the Company also completed the key acquisition of Jayex UK and its *Enlighten* business, which been deployed across approximately 1,900 clinics and 33 hospitals in the UK. This involved the cash consideration payment of \$2.1m and issue of 19,003,378 shares in the Company.

To support the planned growth and expansion, the Company has expanded its leadership team of key executives including:

- Mr Agam Jain - as an Executive Director of the Company, based in London and responsible for UK, USA and Europe. Mr Jain has more than 30 years' tenure as the founder and Managing Director of Jayex UK
- Mr Nick Fernando - CEO and Managing Director of Jayex UK. Mr Fernando has previously been employed by Phillips Healthcare and Exelis VIS where he was Managing Director of Europe
- Mr Cameron Knox – Chief Financial Officer. Mr Knox has over 10 years' experience in the finance and accounting sector

Key Points – Financial

During the Quarter the net operating and investing cash outflows were \$2.8m, including a \$2.1m payment for the Company's new investment in Jayex Technologies Limited (Jayex UK). In addition borrowings of approximately \$1.5m were repaid during the Quarter, including a \$1.2m loan repaid by Jayex UK from its existing cash holdings.

The Company also completed its Initial Public Offering and listing on the ASX Limited on 18 December 2015. The proceeds of the IPO were \$8m (before costs). These funds provide working capital to fund operational, marketing and technology based initiatives which will accelerate the Company's growth.

The cash balance at 31 December 2015 was \$4.6m million.

The Appendix 4C for the Quarter is set out below. These cash flows include post-acquisition cash flows from Jayex UK from 18 December 2015. As the Company has adopted a financial year ending on 31 December, "year to date" information is for the 12 months ended 31 December 2015.

ENDS

Contacts for further information:

Executive Chairman
Michael Boyd
0447 600 888

Company Secretary
Melanie Leydin
0417 663 119

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service ; and
- the *BluePoint*® remote pharmacy prescription processing and dispensing terminal.

Jayex offers 24/7, online, interconnected 'end-to-end' and 'state-of-the-art' healthcare service delivery platforms for:

- Patients – particularly the “time-poor”, the elderly and chronically ill who would likely benefit from better quality and more convenient healthcare services; and
- GPs/Healthcare professionals, clinics, pharmacies and hospitals – particularly those who want to deliver better healthcare services and enhanced patient well-being, more efficiently and at a lower cost, while at the same time, having the potential to increase their productivity, efficiency and profitability.

The Jayex technologies are designed to meet the demands and expectations of patients, GPs, AHPs, clinics, pharmacies and hospitals in today's market, and has the versatility and flexibility to accommodate future demands.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

JAYEX HEALTHCARE LIMITED

ABN

15 119 122 477

Quarter ended ("current quarter")

31 December 2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers	874	1,550
1.2 Payments for		
(a) staff costs	(647)	(1,118)
(b) advertising and marketing	(106)	(137)
(c) research and development	(228)	(253)
(d) leased assets		
(e) other working capital	(594)	(1,288)
1.3 Dividends received		
1.4 Interest and other items of a similar nature received	26	26
1.5 Interest and other costs of finance paid	-	(22)
1.6 Income taxes paid		
1.7 Other (provide details if material)		
Net operating cash flows	(675)	(1,242)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (12 months) \$A'000
1.8 Net operating cash flows (carried forward)	(675)	(1,242)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)		
(b) equity investments	(2,127)	(2,127)
(c) intellectual property		
(d) physical non-current assets		
(e) other non-current assets		
1.10 Proceeds from disposal of:		
(a) businesses (item 5)		
(b) equity investments		
(c) intellectual property		
(d) physical non-current assets		
(e) other non-current assets		
1.11 Loans to other entities		
1.12 Loans repaid by other entities		
1.13 Other (provide details if material)		
Net investing cash flows	(2,127)	(2,127)
1.14 Total operating and investing cash flows	(2,802)	(3,369)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	8,000	8,000
1.16 Payments for capital raising costs	(699)	(828)
1.17 Proceeds from borrowings (convertible notes)	-	1,000
Proceeds from borrowings (other)		40
1.18 Repayment of borrowings – bank loan	(1,241)	(1,241)
Repayment of borrowings – shareholder loans	(243)	(437)
1.19 Dividends paid		
1.20 Other (provide details if material)	-	(6)
Net financing cash flows	5,817	6,528
Net increase (decrease) in cash held	3,015	3,159
1.21 Cash at beginning of quarter/year to date	182	12
1.21.a Cash acquired on acquisitions	1,493	1,519
1.22 Exchange rate adjustments to item 1.21.a	(62)	(62)
1.23 Cash at end of quarter	4,628	4,628

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	-
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	-	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

19,003,378 shares were issued by the Company at \$0.32 per share to vendor of Jayex Technologies Limited (JUK) as part of the consideration paid by the Company to acquire JUK.

Convertible notes payable by the Company, with a face value of \$1,000,000 plus accrued interest of \$26,182 were converted to shares in the Company. 3,772,739 shares in the Company were issued to convertible note holders at \$0.272 per share upon conversion of the notes.

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash


Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	4,628	182
4.2	Deposits at call		
4.3	Bank overdraft		
4.4	Other (provide details)		
Total: cash at end of quarter (item 1.23)		4,628	182

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	Jayex Technologies Limited	-
5.2	Place of incorporation or registration	United Kingdom	-
5.3	Consideration for acquisition or disposal	\$9,082,378	-
5.4	Total net assets	\$3,195,389 (provisional)	-
5.5	Nature of business	Development and sales of health services workflow hardware and software systems.	-

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Sign here:
 (Company secretary)

Date: 29 January 2016

Print name: MELANIE LEYDIN

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.